Sugi Predict

Sugi Predict / Compounds / SCHEMBL4160987

SCHEMBL4160987

SCHEMBL4160987

O=C(O)CCc1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)C4CCCCC4)cc3c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGLN2 Q96KS0 3/20 0.40
▸ EGLN1 Q9GZT9 1/20 0.40
▸ HPGD P15428 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ FFAR4 Q5NUL3 1/20 0.35
▸ GPR17 Q13304 1/20 0.34
▸ BRD4 O60885 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ KDM4E B2RXH2 3/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ PDGFRB P09619 1/20 0.33
▸ FGFR1 P11362 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ PNP P00491 1/20 0.32
▸ PARG Q86W56 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ GRIN2D O15399 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4153172 0.86 TDP1 (0.50) HPGDCYP2C19BRD4LMNATP53
SCHEMBL4157648 0.86 TDP1 (0.50) HPGDCYP2C19BRD4LMNATP53
SCHEMBL4155191 0.84 HPGD (0.42) HPGDCYP2C19GPR17MAPTKDM4E
SCHEMBL3249121 0.83 KDM4E (0.39) EGLN2EGLN1HPGDCYP2C19BRD4
SCHEMBL4162915 0.83 PDGFRB (0.46) HPGDCYP2C19GPR17MAPTPDGFRB
SCHEMBL4153573 0.83 PARG (0.52) HPGDCYP2C19GPR17BRD4LMNA
SCHEMBL4170125 0.82 KDM4E (0.47) HPGDCYP2C19LMNAMAPTKDM4E
Hydrochloric Acid SCHEMBL4167766 0.82 MC4R (0.33) EGLN2EGLN1HPGDCYP2C19
Hydrochloric Acid SCHEMBL4166104 0.82 MC4R (0.33) EGLN2EGLN1HPGDCYP2C19
Hydrochloric Acid SCHEMBL4166100 0.82 MC4R (0.33) EGLN2EGLN1HPGDCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 — — US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 — — US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 — — US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 EGLN2 1653/4885EGLN1 2497/4885HPGD 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.